New model predicts risk of recurrence in early stage colon cancer patients
Overturning a century of prevailing thought, scientists are finding that neurons in the adult brain can remodel their connections. In work reported in the Nov. 24 online edition of the Proceedings of the National Academy of Sciences (PNAS) , Elly Nedivi, associate professor of neurobiology at the Picower Institute for Learning and Memory, and colleagues
Full Post: Neurons in adult brain can remodel their connections
Researchers in the Duke Institute for Genome Sciences & Policy have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens.
“These findings have important implications for individualizing therapy,” said Katherine Garman, M.D., a gastroenterology fellow at Duke and lead investigator on the study. “By examining gene expression in early-stage colon cancer tumors, we have found certain patterns that seem to put some patients at higher risk for recurrence. By identifying these patients up front, we may be able to treat them in a targeted and proactive manner to prevent this recurrence and help them live longer and healthier lives.”
The findings are due to appear in the online edition of the Proceedings of the National Academy of Sciences, between November 24 and November 26, 2008. The study was funded by the Emilene Brown Cancer Research Fund and the National Institutes of Health.
The researchers studied gene expression data from 52 samples of early stage colon cancer tumors, looking for patterns. Then they correlated the gene expression patterns with patient progress reports to track the recurrence of cancer. The predictive power of the correlations was subsequently tested in two independent data sets from 55 and 73 tumors, respectively.
“In our small dataset, we were able to predict which tumors were at risk for recurring, with 90 percent accuracy,” Garman said.
In collaboration with colon cancer specialist David Hsu, M.D., the researchers then took their study one very significant step further, using the data garnered about gene expression and prognosis to examine response to several different types of therapy.
“Importantly, we found that the traditional chemotherapy given to patients with colon cancer varies considerably in its ability to treat tumors with a high likelihood of cancer recurrence,” Garman said. “Using the gene-expression data to guide us, we then identified several other drugs and tested those drugs in our samples. The drugs chosen were novel targeted therapies and anti-inflammatory agents that go after certain cancer cell pathways and had been previously shown to alter colon cancer biology.”
“Two of the drugs we tested seemed to cause significant changes in tumor biology in a laboratory dish, effectively making a high-recurrence-risk tumor into a low-recurrence-risk tumor by altering the genetic makeup,” Garman said. “These therapies would need to be tested further in a clinical trial.”
Conventional methods of characterizing tumors currently rely on pathological information such as tumor size, lymph node involvement and degree of metastasis, Garman said. Doctors use these kinds of clinical data to determine whether an early stage colon cancer patient receives chemotherapy after surgery, and if so, what type.
“Integration of genomic and genetic markers will revolutionize the way we care for patients,” Garman said.
“This is a perfect example of how science can change the way cancer care is practiced,” said Anil Potti, M.D., a researcher in the Duke Institute for Genome Sciences & Policy and senior investigator on this study. “We hope that advances such as this will individualize the treatment plans for patients with colon cancer and improve survival.”
About 150,000 people are diagnosed with colorectal cancer each year in the United States and almost 50,000 are expected to die of the disease in 2008. Up to 30 percent of patients diagnosed with early stage colon cancer can go on to experience recurrences despite initial cure with surgery and chemotherapy when indicated.
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. The findings, presented today
Full Post: Early-stage breast cancer patients with HER2 positive tumors at increased risk of recurrence
The metastasis or spread of breast cancer to other tissues in the body can be predicted more accurately by examining subnetworks of gene expression patterns in a patient’s tumor, than by conventional gene expression microarrays, according to a presentation at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San
Full Post: Gene subnetworks provide new prognostic markers for breast cancer
Findings from a new study have prompted Mayo Clinic researchers to recommend CYP2D6 gene testing for postmenopausal women about to begin tamoxifen therapy. This data confirms that women with an inherited deficiency in the CYP2D6 gene, which is important for the metabolism of tamoxifen, have a nearly fourfold higher risk of early breast cancer recurrence
Full Post: Postmenopausal patients being considered for tamoxifen therapy should be tested for CYP2D6 gene deficiency
Cancer researchers at the Max Delbr?nter for Molecular Medicine (MDC) Berlin-Buch and the Charité - Universit? Medizin Berlin (Germany) have identified a gene which enables them to predict for the first time with high probability if colon cancer is going to metastasize. Assistant Professor Dr. Ulrike Stein, Professor Peter M. Schlag, and Professor Walter Birchmeier
Full Post: Scientists find gene that is a powerful predictor of colon cancer metastasis
Cincinnati scientists have identified a new biomarker that could help predict a person’s risk of developing colon cancer and how aggressive it may become. The University of Cincinnati (UC) team has identified “hotspots”-areas of deleted genetic data-that play a critical role in regulating gene expression and influence colon cancer progression. Researchers speculate that these hotspots
Full Post: Potential new biomarker for colon cancer